Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance [Yahoo! Finance]
LowReport
Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance [Yahoo! Finance]
LeMaitre Vascular, Inc. (NASDAQ: LMAT) had its price target raised by analysts at JMP Securities from $72.00 to $77.00. They now have a "market outperform" rating on the stock.
MediumReport
LeMaitre Vascular, Inc. (NASDAQ: LMAT) had its price target raised by analysts at JMP Securities from $72.00 to $77.00. They now have a "market outperform" rating on the stock.
LeMaitre Vascular, Inc. (NASDAQ: LMAT) had its price target raised by analysts at Barrington Research from $69.00 to $79.00. They now have an "outperform" rating on the stock.
MediumReport
LeMaitre Vascular, Inc. (NASDAQ: LMAT) had its price target raised by analysts at Barrington Research from $69.00 to $79.00. They now have an "outperform" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: